ClinicalTrials.gg
CompletedNCT02135848Updated Oct 20, 2017Results posted

3 Month PHI PAD PoM Study

A Phase 2 interventional study of GSK1278863 and Placebo in Vascular Disease, Peripheral, sponsored by GlaxoSmithKline. Completed at 12 sites in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2017-10-20.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Basic science

From the registry’s dates

  • Registered 1 year 8 months after the study started (first participant enrolled Oct 2010, registered Jun 2012).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 187 studies in Peripheral Vascular Diseases with a site in United States — 18 open to participants now, 23 under way, 2 of them phase 3. Peripheral Vascular Diseases · United States.

Enrollment
98th of 158
46 · median 82
Started
2010
with 7 others
Phase 2
24 of 187
1 open now
Registered
103rd of 187
by date

Among the 187 studies in Peripheral Vascular Diseases with a site in United States, this one is the 98th largest by enrollment of the 158 interventional ones that give a count, is one of 8 that started in 2010, is one of 24 in phase 2, and was the 103rd registered.

Peripheral Vascular Diseases

443 studies on the registry are indexed under Peripheral Vascular Diseases; 44 are open to participants now.

Browse Peripheral Vascular Diseases studies →

Open to participants now

18 of the 187 studies in Peripheral Vascular Diseases with a site in United States are open now. Recruiting first, the newest first:

13 more — sign in →

All 18 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 32 Peripheral Vascular Diseases studies recruiting now, 19 (59%) set no upper age limit and 4 (13%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 187 studies in Peripheral Vascular Diseases with a site in United States, or all of them as a file.
02

Study summary

This is a multi-center, randomized, blinded, placebo controlled study to evaluate the safety of GSK1278863 and its acute and short-term (e.g. 14d) effects on calf muscle endurance and walking ability in subjects with PAD and symptomatic claudication.

Read the detailed description

This is a multi-center, randomized, blinded, placebo controlled study to evaluate the safety of GSK1278863 and its acute and short-term (e.g. 14d) effects on calf muscle endurance and walking ability in subjects with PAD and symptomatic claudication. Functional assessments will be performed following a single high dose (300mg), a single low dose (15mg), and following 14 days of low dose treatment (15mg q.d.). The objectives of this study are to: 1) Evaluate the safety and tolerability of GSK1278863 administered as a single dose and as sub-chronic low dosing (i.e. 14 days) in subjects with peripheral artery disease; 2) To demonstrate the potential pharmacodynamic effect of GSK1278863 on functional measures of calf muscle endurance and fatigability and timed walking distance following a single high or low dose and after 14 days of multiple low dose administration in subjects with claudication-limited peripheral artery disease. In this hypothesis-generating study, multiple assessments of ambulatory and skeletal muscle function will be made during standardized tests of claudication-limited exercise performance, and 3). Characterize the relationship, if any, between the doses and plasma concentrations of GSK1278863 and the pharmacodynamic effects.

03

Conditions studied

  • Vascular Disease, Peripheral
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects ≥ 40 years of age.
  • Male subjects must use one of the methods listed in Section 8.1 for 90 days post-last dose.
  • Females must be , surgically sterilized, or practicing a suitable method of birth control so that in the opinion of the investigator they will not become pregnant during the course of the study.

A female subject is eligible to participate if she is of and agrees to use one of the contraception methods listed in Section 8.1 for an appropriate period of time (as determined by the product label or investigator) prior to the start of dosing to sufficiently minimize the risk of pregnancy at that point. Female subjects must agree to use contraception until 30 days post-last dose.

  • Peripheral artery disease defined as an ankle-brachial index (ABI) at rest ≤ 0.90 in at least one leg in which the patient experiences claudication. For all subsequent evaluations, the Index Leg refers to the symptomatic leg with the lowest ABI.
  • Claudication symptoms with stable severity for at least 3 months prior to screening.
  • The patient is able to provide written to participate in this study.
  • and ALT \< 2xULN; alkaline phosphatase and greater than or equal too 1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%).
  • Confirmed or QTcF \< 450 msec; or QTc \< 480 msec in subjects with bundle branch block.
  • Subjects must be able to perform performance/exercise testing

Exclusion criteria

Exclusion Criteria:

  • Coronary artery bypass graft (CABG), open peripheral vascular procedures, or major surgical procedures within 6 months prior to screening or patients likely to require revascularization during the course of the trial. Endovascular procedures within 3 months prior to screening.
  • Any unstable vascular syndromes (such as , CVA, unstable angina or acute MI), including major changes to related medications, within 6 months prior to randomization.
  • Critical leg ischemia classified as Fontaine Stage III-IV (rest pain, tissue necrosis or gangrene).
  • Pregnant or nursing women (women capable of childbearing must have a negative pregnancy test).
  • A value at screening is:

Male subjects or females: > 15.5 g/dL Female subjects: > 14.5 g/dL

  • Active or diagnosis of malignancy within 5 years prior to screening (excluding successfully treated basal or squamous cell carcinoma).
  • Other cardiovascular, pulmonary, renal, endocrine, hepatic, neurological, psychiatric, immunological, gastrointestinal, hematological, or metabolic disease that is, in the opinion of the Investigator or the Medical Monitor, not stabilized or may otherwise confound the results of the study.
  • Patients with a baseline medical history of proliferative diabetic retinopathy, preproliferative diabetic retinopathy, or wet age-related macular degeneration (AMD)
  • Previously enrolled in a gene therapy clinical study unless patient was randomized to placebo.
  • Plans to initiate a formal exercise training program during the course of the study, or initiation of a formal exercise training program within 3 months prior to screening.
  • Poorly controlled hypertension (defined as seated resting BP >160 mmHg systolic or > 95 mmHg diastolic, or both).
  • Hypotension (defined as seated resting BP \< 95 mmHg systolic or \< 55 mmHg diastolic, or both, or symptomatic hypotension [seated, supine, or orthostatic]).
  • Exercise tolerance, including bilateral heel raise and Six-Minute Walk Test performance, that is limited by co-morbid conditions or diseases other than claudication.
  • Poorly controlled diabetes defined as (HbA1c) > 10%.
  • Creatinine > 2.5 mg/dL or undergoing hemodialysis.
  • Thrombocytopenia defined as count \< 100,000/mm3 at screening.
  • Hematocrit ≤ 30% or ≥ 55%.
  • (INR) > 1.5.
  • A positive surface antigen or positive antibody result if performed within 3 months of screening (testing not required at Screening).
  • History of alcohol or drug abuse, or a significant medical or psychiatric disorder that may impair compliance with the requirements of the protocol.
  • The patient has received an drug within 30 days prior to this study.
  • The patient is enrolled or plans to enroll in another clinical trial during this study
  • History of venous thrombosis, defined as deep vein thrombosis, pulmonary embolism or other venous thrombotic condition, within 1 year prior to Screening.
  • Acute peptic ulcer disease or history of chronic rectal bleeding.
  • Patients with a pre-existing condition interfering with normal gastrointestinal anatomy or motility, and/or hepatic function that could interfere with the absorption, metabolism, and/or excretion of the study drugs. Examples of conditions that could interfere with normal gastrointestinal anatomy or motility include gastrointestinal bypass surgery, partial or total gastrectomy, small bowel resection, vagotomy, malabsorption, Crohn's disease, ulcerative colitis, or celiac sprue.
  • Use of prescription drugs within 7 days prior to first dose of study drug (Day 1) until after completion of all study drug doses and Day 35 assessments:

which are known to be inhibitors of CYP 2C8 OR which are known to be both CYP 2C8 and OATP1B1 substrates OR which rely mainly on OATP1B1/1B3 for hepatic clearance as described in Section 9 of the protocol.

  • Use of prescription drugs within 14 days prior to first dose of study drug (Day 1) until completion of all study drug doses and Day 35 assessments, which are known to be inducers of CYP 2C8, as described in Section 9 of the protocol.
  • Use of non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study drug (Day 1) through the Follow-up Visit (Day 65), unless, in the opinion of the Investigator, medication will not interfere with the study procedures or compromise subject safety and GSK Medical Monitor concurs.
  • History of sensitivity to any of the study drugs, or components thereof, or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation.
  • Patient is mentally or legally incapacitated.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
46 participants (actual)

Study arms

  • Experimental
    GSK1278863

    Study Drug

    Drug: GSK1278863

  • Placebo comparator
    Placebo

    Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)

    AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. For marketed medicinal products, this also includes failure to produce expected benefits (i.e., lack of efficacy), abuse or misuse. SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect or is medically significant.

    Time frame: Up to 67 days

  2. Number of Participants With Abnormal Electrocardiogram (ECG) Findings

    Twelve lead ECGs were recorded with the participant lying supine, having rested in this position for at least 5 minutes before each recording. Full 12 lead ECGs were recorded using an ECG device that automatically calculated the heart rate and measured PR, QRS, RR, QT and QT, QT corrected by Bazett's formula (QTcB) and QT corrected by Fridericia's formula (QTcF) intervals. Number of participants with abnormal (not clinically significant \[NCS\] and clinically significant \[CS\]) ECG findings are presented.

    Time frame: Up to 39 days

  3. Number of Participants With Vital Signs of Potential Clinical Importance

    Vital signs included heart rate, systolic and diastolic blood pressure and were performed with the participant in a supine position after the participant had rested for at least 5 minutes. Number of participants with vital signs of potential clinical importance are presented.

    Time frame: Up to 39 days

  4. Number of Participants With Clinical Chemistry Abnormalities of Potential Clinical Importance

    Clinical chemistry analyte of potential clinical concern included albumin, calcium, creatinine, glucose, magnesium, phosphorus, potassium, sodium and bicarbonate. Number of participants with clinical chemistry abnormalities of potential clinical importance are presented.

    Time frame: Up to 67 days

  5. Number of Participants With Clinical Hematology Abnormalities of Potential Clinical Importance

    Hematology parameters included platelet count, red blood cell (RBC) count, white blood cell WBC count (absolute), hemoglobin, hematocrit, Mean corpuscular volume (MCV), Mean corpuscular hemoglobin (MCH), Mean corpuscular hemoglobin concentration (MCHC), neutrophils, lymphocytes, monocytes, eosinophils and basophils. Number of participants with clinical hematology abnormalities of potential clinical importance are presented.

    Time frame: Up to 67 days

Secondary outcomes

  1. Change From Baseline in Total Number of Contractions to Onset of Claudication

    At Visit 1 (-21 to -10 days), the participant was introduced to the bilateral heel raise test (BHRT). Test familiarization consisted of the participant performing heel raises to the onset of claudication. The BHRT was conducted with an electrogoniometer instrumented on the index leg. Successive heel raise repetitions were performed once every other second until the participant stopped due to intolerable claudication pain or fatigue, or other criteria for stopping the test were met. The index leg was defined as the leg that met the inclusion symptomatic and hemodynamic criteria (ankle brachial index \[ABI\] ≤ 0.90) with the lowest ABI considered if both legs were affected. Baseline was Day 1. Change from Baseline was post-Baseline values minus Baseline values.

    Time frame: Baseline (Day 1) to Day 39

  2. Change From Baseline in Total Work Performed to Onset of Claudication

    BHRT is a method to assess muscle performance in participants with claudication. Participants with peripheral artery disease (PAD) and claudication experience reproducible symptoms of leg pain during walking exercise. The symptom of claudication is due to exercise-induced ischemia of muscles in legs, most commonly in calf muscles. At Visit 1 (-21 to -10 days), the participant was introduced to BHRT. Test familiarization consisted of the participant performing heel raises to onset of claudication. BHRT was conducted with an electrogoniometer instrumented on the index leg (leg that met the inclusion symptomatic and hemodynamic criteria \[ABI ≤ 0.90\] with the lowest ABI considered if both legs were affected). Successive heel raise repetitions were performed once every other second until participant stopped due to intolerable claudication pain/fatigue, or other criteria for stopping the test were met. Baseline was Day 1. Change from Baseline was post-Baseline values minus Baseline values.

    Time frame: Baseline (Day 1) to Day 39

  3. Change From Baseline in Total Exercise Time to Onset of Claudication

    BHRT is a method to assess muscle performance in participants with claudication. Participants with PAD and claudication experience reproducible symptoms of leg pain during walking exercise. The symptom of claudication is due to exercise-induced ischemia of muscles in legs, most commonly in calf muscles. At Visit 1 (-21 to -10 days), the participant was introduced to the BHRT. Test familiarization consisted of the participant performing heel raises to the onset of claudication. The BHRT was conducted with an electrogoniometer instrumented on the index leg (the leg that met the inclusion symptomatic and hemodynamic criteria \[ABI ≤ 0.90\] with the lowest ABI considered if both legs were affected). Successive heel raise repetitions were performed once every other second until the participant stopped due to intolerable claudication pain or fatigue, or other criteria for stopping the test were met. Baseline was Day 1. Change from Baseline was post-Baseline values minus Baseline values.

    Time frame: Baseline (Day 1) to Day 39

  4. Change From Baseline in Total Number of Contractions to Claudication-limited Maximal Muscle Performance

    BHRT is a method to assess muscle performance in participants with claudication. Participants with PAD and claudication experience reproducible symptoms of leg pain during walking exercise. The symptom of claudication is due to exercise-induced ischemia of muscles in legs, most commonly in calf muscles. At Visit 1 (-21 to -10 days), the participant was introduced to the BHRT. Test familiarization consisted of the participant performing heel raises to the onset of claudication. The BHRT was conducted with an electrogoniometer instrumented on the index leg (the leg that met the inclusion symptomatic and hemodynamic criteria \[ABI ≤ 0.90\] with the lowest ABI considered if both legs were affected). Successive heel raise repetitions were performed once every other second until the participant stopped due to intolerable claudication pain or fatigue, or other criteria for stopping the test were met. Baseline was Day 1. Change from Baseline was post-Baseline values minus Baseline values.

    Time frame: Baseline (Day 1) to Day 39

  5. Change From Baseline in Total Work Performed to Claudication-limited Maximal Muscle Performance

    BHRT is a method to assess muscle performance in participants with claudication. Participants with PAD and claudication experience reproducible symptoms of leg pain during walking exercise. The symptom of claudication is due to exercise-induced ischemia of muscles in legs, most commonly in calf muscles. At Visit 1 (-21 to -10 days), the participant was introduced to the BHRT. Test familiarization consisted of the participant performing heel raises to the onset of claudication. The BHRT was conducted with an electrogoniometer instrumented on the index leg (the leg that met the inclusion symptomatic and hemodynamic criteria \[ABI ≤ 0.90\] with the lowest ABI considered if both legs were affected). Successive heel raise repetitions were performed once every other second until the participant stopped due to intolerable claudication pain or fatigue, or other criteria for stopping the test were met. Baseline was Day 1. Change from Baseline was post-Baseline values minus Baseline values.

    Time frame: Baseline (Day 1) to Day 39

  6. Change From Baseline in Total Exercise Time to Claudication-limited Maximal Muscle Performance

    BHRT is a method to assess muscle performance in participants with claudication. Participants with PAD and claudication experience reproducible symptoms of leg pain during walking exercise. The symptom of claudication is due to exercise-induced ischemia of muscles in legs, most commonly in calf muscles. At Visit 1 (-21 to -10 days), the participant was introduced to the BHRT. Test familiarization consisted of the participant performing heel raises to the onset of claudication. The BHRT was conducted with an electrogoniometer instrumented on the index leg (the leg that met the inclusion symptomatic and hemodynamic criteria \[ABI ≤ 0.90\] with the lowest ABI considered if both legs were affected). Successive heel raise repetitions were performed once every other second until the participant stopped due to intolerable claudication pain or fatigue, or other criteria for stopping the test were met. Baseline was Day 1. Change from Baseline was post-Baseline values minus Baseline values.

    Time frame: Baseline (Day 1) to Day 39

  7. Change From Baseline in the Maximal Distance Covered During a Six-Minute Walk Test

    The Six-Minute Walk Test was performed by the participant walking at a self-selected pace for 6 minutes through a pre-defined walking course. When the Six-Minute Walk Test and Bilateral Heel Raise Test were conducted at the same study visit, the participant was allowed to rest a minimum of one hour between these tests. Baseline was Day 1. Change from Baseline was post-Baseline values minus Baseline values.

    Time frame: Baseline (Day 1) to Day 39

  8. Change From Baseline in Erythropoietin Concentration

    Blood samples for analysis of fasting levels of erythropoietin, was collected up to end of treatment or early termination. Baseline acute was Day 1 and Baseline chronic was Day 21. Change from Baseline was post-Baseline values minus Baseline values.

    Time frame: Baseline (Day 1) to Day 39

  9. Change From Baseline in Hemoglobin

    Blood samples for analysis of fasting levels of hemoglobin was collected up to end of treatment or early termination. Baseline acute was Day 1 and Baseline chronic was Day 21. Change from Baseline was post-Baseline values minus Baseline values.

    Time frame: Baseline (Day 1) to Day 39

  10. Change From Baseline in Hematocrit

    Blood samples for analysis of fasting levels of hematocrit was collected up to end of treatment or early termination. Baseline acute was Day 1 and Baseline chronic was Day 21. Change from Baseline was post-Baseline values minus Baseline values.

    Time frame: Baseline (Day 1) to Day 39

  11. Change From Baseline in High Sensitivity C-reactive Protein (hsCRP)

    Blood samples for analysis of fasting levels of hsCRP, was collected up to end of treatment or early termination. Baseline acute was Day 1 and Baseline chronic was Day 21. Change from Baseline was post-Baseline values minus Baseline values.

    Time frame: Baseline (Day 1) to Day 39

  12. Change From Baseline in Lipids (Total Cholesterol [TC], Triglycerides [TG], High Density Lipoprotein Cholesterol [HDLc] and Low Density Lipoprotein Cholesterol [LDLc])

    Blood samples for analysis of fasting levels of lipid panel (TC, TG, HDLc and LDLc) was collected up to end of treatment or early termination. Baseline acute was Day 1 and Baseline chronic was Day 21. Change from Baseline was post-Baseline values minus Baseline values.

    Time frame: Baseline (Day 1) to Day 39

  13. Derived Plasma GSK1278863 Pharmacokinetic Parameter- Maximum Plasma Concentration (Cmax) and Trough Concentration (Ctau)

    Blood samples for pharmacokinetic analysis of GSK1278863 and selected metabolites were collected at the following time points: Visit 2-Baseline acute: pre-dose, 1 hour, 2 hours and 3.5 hours post-dose, Visit 3-post acute, Visit 4-rescreen, Visit 5-Baseline chronic and end of treatment or early termination. The actual date and time of each blood sample collection was recorded.

    Time frame: Visit 2 (Day 1): pre-dose, 1 hour, 2 hours and 3.5 hours post-dose, Visit 3 (Day 2)-post acute, Visit 4 (Day 16)-rescreen, Visit 5 (Day 23)-Baseline chronic and end of treatment (14 days after Visit 5) or early termination (between Visit 2 and 6)

  14. Derived Plasma GSK1278863 Pharmacokinetic Parameter -Area Under the Curve (AUC [0-t])

    Blood samples for pharmacokinetic analysis of GSK1278863 and selected metabolites were collected at the following time points: Visit 2-Baseline acute: pre-dose, 1 hour, 2 hours and 3.5 hours post-dose, Visit 3-post acute, Visit 4-rescreen, Visit 5-Baseline chronic and end of treatment or early termination. The actual date and time of each blood sample collection was recorded.

    Time frame: Visit 2 (Day 1): pre-dose, 1 hour, 2 hours and 3.5 hours post-dose, Visit 3 (Day 2)-post acute, Visit 4 (Day 16)-rescreen, Visit 5 (Day 23)-Baseline chronic and end of treatment (14 days after Visit 5) or early termination (between Visit 2 and 6)

  15. Derived Plasma GSK1278863 Pharmacokinetic Parameter - Time to Maximum Plasma Concentration (T-max) and Last Time Point Where the Concentration is Above the Limit of Quantification (T-last)

    Blood samples for pharmacokinetic analysis of GSK1278863 and selected metabolites were collected at the following time points: Visit 2-Baseline acute: pre-dose, 1 hour, 2 hours and 3.5 hours post-dose, Visit 3-post acute, Visit 4-rescreen, Visit 5-Baseline chronic and end of treatment or early termination. The actual date and time of each blood sample collection was recorded.

    Time frame: Visit 2 (Day 1): pre-dose, 1 hour, 2 hours and 3.5 hours post-dose, Visit 3 (Day 2)-post acute, Visit 4 (Day 16)-rescreen, Visit 5 (Day 23)-Baseline chronic and end of treatment (14 days after Visit 5) or early termination (between Visit 2 and 6)

  16. Relationship of Pharmacokinetic Parameters to the Pharmacodynamic Assessments Performed in This Study

    A formal pharmacokinetic /pharmacodynamic analysis and pharmacokinetic /pharmacodynamic modelling for exposure relationships to endpoints was planned. The data for this outcome was not collected.

    Time frame: Visit 2 (Day 1): pre-dose, 1 hour, 2 hours and 3.5 hours post-dose, Visit 3 (Day 2)-post acute, Visit 4 (Day 16)-rescreen, Visit 5 (Day 23)-Baseline chronic and end of treatment (14 days after Visit 5) or early termination (between Visit 2 and 6)

07

Results

Posted Oct 20, 2017

Participant flow

This study was conducted at 12 centers in the United States from 15-October-2010 to 01-November-2011.

Participant flow — Overall Study
MilestoneGSK1278863Placebo
Started2620
Completed2319
Not completed31
Withdrew: Adverse event20
Withdrew: Withdrawal by subject11

Outcome measures

PrimaryNumber of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)

AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. For marketed medicinal products, this also includes failure to produce expected benefits (i.e., lack of efficacy), abuse or misuse. SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect or is medically significant.

Time frame:
Up to 67 days
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)
ParticipantsGSK1278863 300 mgPlacebo Matched With GSK1278863 300 mgGSK1278863 15 mgPlacebo Matched With GSK1278863 15 mg
AE14693
SAE2001
PrimaryNumber of Participants With Abnormal Electrocardiogram (ECG) Findings

Twelve lead ECGs were recorded with the participant lying supine, having rested in this position for at least 5 minutes before each recording. Full 12 lead ECGs were recorded using an ECG device that automatically calculated the heart rate and measured PR, QRS, RR, QT and QT, QT corrected by Bazett's formula (QTcB) and QT corrected by Fridericia's formula (QTcF) intervals. Number of participants with abnormal (not clinically significant \[NCS\] and clinically significant \[CS\]) ECG findings are presented.

Time frame:
Up to 39 days
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Electrocardiogram (ECG) Findings
ParticipantsGSK1278863 300 mgPlacebo Matched With GSK1278863 300 mgGSK1278863 15 mgPlacebo Matched With GSK1278863 15 mg
Acute Day 1, Pre-dose; Abnormal NCS1416——
Acute Day 1, Pre-dose; Abnormal CS00——
Acute Day 1, 2.5 hour; Abnormal NCS1514——
Acute Day 1, 2.5 hour; Abnormal CS00——
Chronic Day 1, Pre-dose; Abnormal NCS——1214
Chronic Day 1, Pre-dose; Abnormal CS——00
Chronic Day 1, 2.5 hour; Abnormal NCS——814
Chronic Day 1, 2.5 hour; Abnormal CS——00
End of treatment, Pre-dose; Abnormal NCS——1514
End of treatment, Pre-dose; Abnormal CS——00
Early termination, Pre-dose; Abnormal NCS2———
Early termination, Pre-dose; Abnormal CS1———
PrimaryNumber of Participants With Vital Signs of Potential Clinical Importance

Vital signs included heart rate, systolic and diastolic blood pressure and were performed with the participant in a supine position after the participant had rested for at least 5 minutes. Number of participants with vital signs of potential clinical importance are presented.

Time frame:
Up to 39 days
Reported as:
Count of participants · Participants
Number of Participants With Vital Signs of Potential Clinical Importance
ParticipantsGSK1278863 300 mgPlacebo Matched With GSK1278863 300 mgGSK1278863 15 mgPlacebo Matched With GSK1278863 15 mg
Number of Participants With Vital Signs of Potential Clinical Importance3123
PrimaryNumber of Participants With Clinical Chemistry Abnormalities of Potential Clinical Importance

Clinical chemistry analyte of potential clinical concern included albumin, calcium, creatinine, glucose, magnesium, phosphorus, potassium, sodium and bicarbonate. Number of participants with clinical chemistry abnormalities of potential clinical importance are presented.

Time frame:
Up to 67 days
Reported as:
Count of participants · Participants
Number of Participants With Clinical Chemistry Abnormalities of Potential Clinical Importance
ParticipantsGSK1278863 300 mgPlacebo Matched With GSK1278863 300 mgGSK1278863 15 mgPlacebo Matched With GSK1278863 15 mg
High Glucose5253
High Calcium0010
High Potassium1121
Low Carbon-dioxide content0011
High Creatinine1010
High Carbon-dioxide content0001
PrimaryNumber of Participants With Clinical Hematology Abnormalities of Potential Clinical Importance

Hematology parameters included platelet count, red blood cell (RBC) count, white blood cell WBC count (absolute), hemoglobin, hematocrit, Mean corpuscular volume (MCV), Mean corpuscular hemoglobin (MCH), Mean corpuscular hemoglobin concentration (MCHC), neutrophils, lymphocytes, monocytes, eosinophils and basophils. Number of participants with clinical hematology abnormalities of potential clinical importance are presented.

Time frame:
Up to 67 days
Reported as:
Count of participants · Participants
Number of Participants With Clinical Hematology Abnormalities of Potential Clinical Importance
ParticipantsGSK1278863Placebo
Number of Participants With Clinical Hematology Abnormalities of Potential Clinical Importance00
SecondaryChange From Baseline in Total Number of Contractions to Onset of Claudication

At Visit 1 (-21 to -10 days), the participant was introduced to the bilateral heel raise test (BHRT). Test familiarization consisted of the participant performing heel raises to the onset of claudication. The BHRT was conducted with an electrogoniometer instrumented on the index leg. Successive heel raise repetitions were performed once every other second until the participant stopped due to intolerable claudication pain or fatigue, or other criteria for stopping the test were met. The index leg was defined as the leg that met the inclusion symptomatic and hemodynamic criteria (ankle brachial index \[ABI\] ≤ 0.90) with the lowest ABI considered if both legs were affected. Baseline was Day 1. Change from Baseline was post-Baseline values minus Baseline values.

Time frame:
Baseline (Day 1) to Day 39
Reported as:
Mean · Contractions
Change From Baseline in Total Number of Contractions to Onset of Claudication
ContractionsGSK1278863Placebo
Acute Day 1, 3 hour2.52 ± 7.7-1.67 ± 6.5
Acute Day 2, Pre-dose3.77 ± 8.6-0.94 ± 4.8
Chronic Day 1, Pre-dose5.68 ± 10.0-1.56 ± 5.1
Chronic Day 1, 3 hour3.00 ± 9.40.83 ± 8.6
End of treatment, Pre-dose2.90 ± 9.2-0.83 ± 6.4
SecondaryChange From Baseline in Total Work Performed to Onset of Claudication

BHRT is a method to assess muscle performance in participants with claudication. Participants with peripheral artery disease (PAD) and claudication experience reproducible symptoms of leg pain during walking exercise. The symptom of claudication is due to exercise-induced ischemia of muscles in legs, most commonly in calf muscles. At Visit 1 (-21 to -10 days), the participant was introduced to BHRT. Test familiarization consisted of the participant performing heel raises to onset of claudication. BHRT was conducted with an electrogoniometer instrumented on the index leg (leg that met the inclusion symptomatic and hemodynamic criteria \[ABI ≤ 0.90\] with the lowest ABI considered if both legs were affected). Successive heel raise repetitions were performed once every other second until participant stopped due to intolerable claudication pain/fatigue, or other criteria for stopping the test were met. Baseline was Day 1. Change from Baseline was post-Baseline values minus Baseline values.

Time frame:
Baseline (Day 1) to Day 39
Reported as:
Mean · kilogram-meters
Change From Baseline in Total Work Performed to Onset of Claudication
kilogram-metersGSK1278863Placebo
Acute Day 1, 3 hour14.66 ± 42.0-8.12 ± 52.5
Acute Day 2, Pre-dose12.46 ± 42.5-14.61 ± 55.2
Chronic Day 1, Pre-dose24.17 ± 38.7-15.69 ± 45.0
Chronic Day 1, 3 hour11.23 ± 40.6-3.03 ± 68.0
End of treatment, Pre-dose8.13 ± 42.1-15.60 ± 59.1
SecondaryChange From Baseline in Total Exercise Time to Onset of Claudication

BHRT is a method to assess muscle performance in participants with claudication. Participants with PAD and claudication experience reproducible symptoms of leg pain during walking exercise. The symptom of claudication is due to exercise-induced ischemia of muscles in legs, most commonly in calf muscles. At Visit 1 (-21 to -10 days), the participant was introduced to the BHRT. Test familiarization consisted of the participant performing heel raises to the onset of claudication. The BHRT was conducted with an electrogoniometer instrumented on the index leg (the leg that met the inclusion symptomatic and hemodynamic criteria \[ABI ≤ 0.90\] with the lowest ABI considered if both legs were affected). Successive heel raise repetitions were performed once every other second until the participant stopped due to intolerable claudication pain or fatigue, or other criteria for stopping the test were met. Baseline was Day 1. Change from Baseline was post-Baseline values minus Baseline values.

Time frame:
Baseline (Day 1) to Day 39
Reported as:
Mean · Seconds
Change From Baseline in Total Exercise Time to Onset of Claudication
SecondsGSK1278863Placebo
Acute Day 1, 3 hour4.39 ± 15.7-3.34 ± 13.4
Acute Day 2, Pre-dose8.00 ± 17.2-3.96 ± 14.4
Chronic Day 1, Pre-dose10.50 ± 19.9-3.71 ± 11.1
Chronic Day 1, 3 hour5.63 ± 18.51.25 ± 18.3
End of treatment, Pre-dose5.03 ± 18.7-1.05 ± 11.8
SecondaryChange From Baseline in Total Number of Contractions to Claudication-limited Maximal Muscle Performance

BHRT is a method to assess muscle performance in participants with claudication. Participants with PAD and claudication experience reproducible symptoms of leg pain during walking exercise. The symptom of claudication is due to exercise-induced ischemia of muscles in legs, most commonly in calf muscles. At Visit 1 (-21 to -10 days), the participant was introduced to the BHRT. Test familiarization consisted of the participant performing heel raises to the onset of claudication. The BHRT was conducted with an electrogoniometer instrumented on the index leg (the leg that met the inclusion symptomatic and hemodynamic criteria \[ABI ≤ 0.90\] with the lowest ABI considered if both legs were affected). Successive heel raise repetitions were performed once every other second until the participant stopped due to intolerable claudication pain or fatigue, or other criteria for stopping the test were met. Baseline was Day 1. Change from Baseline was post-Baseline values minus Baseline values.

Time frame:
Baseline (Day 1) to Day 39
Reported as:
Mean · Contractions
Change From Baseline in Total Number of Contractions to Claudication-limited Maximal Muscle Performance
ContractionsGSK1278863Placebo
Acute Day 1, 3 hour1.00 ± 7.6-2.17 ± 6.4
Acute Day 2, Pre-dose1.48 ± 10.1-0.94 ± 5.6
Chronic Day 1, Pre-dose4.55 ± 8.3-1.83 ± 5.6
Chronic Day 1, 3 hour3.45 ± 10.0-0.67 ± 6.9
End of treatment, Pre-dose3.45 ± 10.1-1.11 ± 8.1
SecondaryChange From Baseline in Total Work Performed to Claudication-limited Maximal Muscle Performance

BHRT is a method to assess muscle performance in participants with claudication. Participants with PAD and claudication experience reproducible symptoms of leg pain during walking exercise. The symptom of claudication is due to exercise-induced ischemia of muscles in legs, most commonly in calf muscles. At Visit 1 (-21 to -10 days), the participant was introduced to the BHRT. Test familiarization consisted of the participant performing heel raises to the onset of claudication. The BHRT was conducted with an electrogoniometer instrumented on the index leg (the leg that met the inclusion symptomatic and hemodynamic criteria \[ABI ≤ 0.90\] with the lowest ABI considered if both legs were affected). Successive heel raise repetitions were performed once every other second until the participant stopped due to intolerable claudication pain or fatigue, or other criteria for stopping the test were met. Baseline was Day 1. Change from Baseline was post-Baseline values minus Baseline values.

Time frame:
Baseline (Day 1) to Day 39
Reported as:
Mean · kilogram-meters
Change From Baseline in Total Work Performed to Claudication-limited Maximal Muscle Performance
kilogram-metersGSK1278863Placebo
Acute Day 1, 3 hour11.32 ± 46.1-6.20 ± 53.4
Acute Day 2, Pre-dose5.11 ± 55.4-11.35 ± 62.2
Chronic Day 1, Pre-dose22.20 ± 36.5-10.84 ± 62.3
Chronic Day 1, 3 hour14.40 ± 46.8-4.04 ± 68.9
End of treatment, Pre-dose6.75 ± 37.1-14.22 ± 75.6
SecondaryChange From Baseline in Total Exercise Time to Claudication-limited Maximal Muscle Performance

BHRT is a method to assess muscle performance in participants with claudication. Participants with PAD and claudication experience reproducible symptoms of leg pain during walking exercise. The symptom of claudication is due to exercise-induced ischemia of muscles in legs, most commonly in calf muscles. At Visit 1 (-21 to -10 days), the participant was introduced to the BHRT. Test familiarization consisted of the participant performing heel raises to the onset of claudication. The BHRT was conducted with an electrogoniometer instrumented on the index leg (the leg that met the inclusion symptomatic and hemodynamic criteria \[ABI ≤ 0.90\] with the lowest ABI considered if both legs were affected). Successive heel raise repetitions were performed once every other second until the participant stopped due to intolerable claudication pain or fatigue, or other criteria for stopping the test were met. Baseline was Day 1. Change from Baseline was post-Baseline values minus Baseline values.

Time frame:
Baseline (Day 1) to Day 39
Reported as:
Mean · seconds
Change From Baseline in Total Exercise Time to Claudication-limited Maximal Muscle Performance
secondsGSK1278863Placebo
Acute Day 1, 3 hour0.15 ± 14.7-5.41 ± 13.3
Acute Day 2, Pre-dose2.18 ± 21.1-5.06 ± 15.8
Chronic Day 1, Pre-dose5.71 ± 15.7-4.91 ± 12.3
Chronic Day 1, 3 hour4.89 ± 18.6-2.92 ± 15.2
End of treatment, Pre-dose4.59 ± 21.1-2.69 ± 15.7
SecondaryChange From Baseline in the Maximal Distance Covered During a Six-Minute Walk Test

The Six-Minute Walk Test was performed by the participant walking at a self-selected pace for 6 minutes through a pre-defined walking course. When the Six-Minute Walk Test and Bilateral Heel Raise Test were conducted at the same study visit, the participant was allowed to rest a minimum of one hour between these tests. Baseline was Day 1. Change from Baseline was post-Baseline values minus Baseline values.

Time frame:
Baseline (Day 1) to Day 39
Reported as:
Mean · Feet
Change From Baseline in the Maximal Distance Covered During a Six-Minute Walk Test
FeetGSK1278863Placebo
Acute Day 1, 2 hour-52.88 ± 140.3-11.60 ± 64.3
Acute Day 2, Pre-dose-42.25 ± 160.9-7.11 ± 116.2
Chronic Day 1, Pre-dose8.43 ± 139.7-31.89 ± 138.6
Chronic Day 1, 2 hour-6.43 ± 145.2-26.53 ± 166.6
End of treatment, Pre-dose14.57 ± 163.9-47.47 ± 192.8
SecondaryChange From Baseline in Erythropoietin Concentration

Blood samples for analysis of fasting levels of erythropoietin, was collected up to end of treatment or early termination. Baseline acute was Day 1 and Baseline chronic was Day 21. Change from Baseline was post-Baseline values minus Baseline values.

Time frame:
Baseline (Day 1) to Day 39
Reported as:
Mean · Units per Liter
Change From Baseline in Erythropoietin Concentration
Units per LiterGSK1278863Placebo
Acute Day 1, 2.5 hour8.10 ± 14.119-2.54 ± 3.718
Acute Day 1, 3 hour53.98 ± 87.176-2.25 ± 4.416
Acute Day 2, Pre-dose907.43 ± 561.105-0.79 ± 6.889
Chronic Day 1, Pre-dose-1.05 ± 8.228-2.39 ± 6.275
Chronic Day 1, 2.5 hour-2.24 ± 7.349-5.18 ± 7.905
Chronic Day 1, 3 hour1.00 ± 8.435-4.81 ± 8.067
End of treatment, Pre-dose0.78 ± 11.360-1.60 ± 13.421
Early termination-10.15 ± 7.283—
SecondaryChange From Baseline in Hemoglobin

Blood samples for analysis of fasting levels of hemoglobin was collected up to end of treatment or early termination. Baseline acute was Day 1 and Baseline chronic was Day 21. Change from Baseline was post-Baseline values minus Baseline values.

Time frame:
Baseline (Day 1) to Day 39
Reported as:
Mean · Grams per Liter
Change From Baseline in Hemoglobin
Grams per LiterGSK1278863Placebo
Acute Day 2, Pre-dose1.29 ± 5.706-0.84 ± 5.776
Chronic Day 1, Pre-dose0.91 ± 7.596-0.44 ± 5.973
End of treatment, Pre-dose9.13 ± 9.221-1.42 ± 5.470
Early termination2.50 ± 2.121—
Follow-up6.36 ± 6.350-1.17 ± 7.786
SecondaryChange From Baseline in Hematocrit

Blood samples for analysis of fasting levels of hematocrit was collected up to end of treatment or early termination. Baseline acute was Day 1 and Baseline chronic was Day 21. Change from Baseline was post-Baseline values minus Baseline values.

Time frame:
Baseline (Day 1) to Day 39
Reported as:
Mean · Fraction
Change From Baseline in Hematocrit
FractionGSK1278863Placebo
Acute Day 2, Pre-dose0.00 ± 0.017-0.00 ± 0.018
Chronic Day 1, Pre-dose0.00 ± 0.0210.00 ± 0.017
End of treatment, Pre-dose0.03 ± 0.029-0.00 ± 0.015
Early termination0.02 ± 0.002—
Follow-up0.02 ± 0.023-0.00 ± 0.023
SecondaryChange From Baseline in High Sensitivity C-reactive Protein (hsCRP)

Blood samples for analysis of fasting levels of hsCRP, was collected up to end of treatment or early termination. Baseline acute was Day 1 and Baseline chronic was Day 21. Change from Baseline was post-Baseline values minus Baseline values.

Time frame:
Baseline (Day 1) to Day 39
Reported as:
Mean · Milligrams/Liter (mg/L)
Change From Baseline in High Sensitivity C-reactive Protein (hsCRP)
Milligrams/Liter (mg/L)GSK1278863Placebo
Acute Day 2, Pre-dose2.51 ± 1.905-0.08 ± 2.183
Chronic Day 1, Pre-dose1.12 ± 2.9090.21 ± 3.550
End of treatment, Pre-dose1.32 ± 3.4670.72 ± 5.625
Early termination-1.50 ± 2.263—
SecondaryChange From Baseline in Lipids (Total Cholesterol [TC], Triglycerides [TG], High Density Lipoprotein Cholesterol [HDLc] and Low Density Lipoprotein Cholesterol [LDLc])

Blood samples for analysis of fasting levels of lipid panel (TC, TG, HDLc and LDLc) was collected up to end of treatment or early termination. Baseline acute was Day 1 and Baseline chronic was Day 21. Change from Baseline was post-Baseline values minus Baseline values.

Time frame:
Baseline (Day 1) to Day 39
Reported as:
Mean · Millimoles/Liter (MMOL/L)
Change From Baseline in Lipids (Total Cholesterol [TC], Triglycerides [TG], High Density Lipoprotein Cholesterol [HDLc] and Low Density Lipoprotein Cholesterol [LDLc])
Millimoles/Liter (MMOL/L)GSK1278863Placebo
TC: End of treatment, Pre-dose-0.69 ± 0.7070.20 ± 0.689
TC: Early termination-0.48 ± 0.460—
TG: End of treatment, Pre-dose0.02 ± 0.8350.27 ± 0.926
TG: Early termination-0.52 ± 1.160—
HDLc: End of treatment, Pre-dose-0.17 ± 0.195-0.04 ± 0.173
HDLc: Early termination0.13 ± 0.177—
LDLc: End of treatment, Pre-dose-0.53 ± 0.4890.12 ± 0.701
LDLc: Early termination-0.37 ± 0.106—
SecondaryDerived Plasma GSK1278863 Pharmacokinetic Parameter- Maximum Plasma Concentration (Cmax) and Trough Concentration (Ctau)

Blood samples for pharmacokinetic analysis of GSK1278863 and selected metabolites were collected at the following time points: Visit 2-Baseline acute: pre-dose, 1 hour, 2 hours and 3.5 hours post-dose, Visit 3-post acute, Visit 4-rescreen, Visit 5-Baseline chronic and end of treatment or early termination. The actual date and time of each blood sample collection was recorded.

Time frame:
Visit 2 (Day 1): pre-dose, 1 hour, 2 hours and 3.5 hours post-dose, Visit 3 (Day 2)-post acute, Visit 4 (Day 16)-rescreen, Visit 5 (Day 23)-Baseline chronic and end of treatment (14 days after Visit 5) or early termination (between Visit 2 and 6)
Reported as:
Geometric mean · Nanogram/milliliter (ng/mL)
Derived Plasma GSK1278863 Pharmacokinetic Parameter- Maximum Plasma Concentration (Cmax) and Trough Concentration (Ctau)
Nanogram/milliliter (ng/mL)GSK1278863 300 mgGSK1278863 15 mg
Cmax3416.37 ± 81.4197.28 ± 80.6
Ctau6.672 ± 131.81.357 ± 19.9
SecondaryDerived Plasma GSK1278863 Pharmacokinetic Parameter -Area Under the Curve (AUC [0-t])

Blood samples for pharmacokinetic analysis of GSK1278863 and selected metabolites were collected at the following time points: Visit 2-Baseline acute: pre-dose, 1 hour, 2 hours and 3.5 hours post-dose, Visit 3-post acute, Visit 4-rescreen, Visit 5-Baseline chronic and end of treatment or early termination. The actual date and time of each blood sample collection was recorded.

Time frame:
Visit 2 (Day 1): pre-dose, 1 hour, 2 hours and 3.5 hours post-dose, Visit 3 (Day 2)-post acute, Visit 4 (Day 16)-rescreen, Visit 5 (Day 23)-Baseline chronic and end of treatment (14 days after Visit 5) or early termination (between Visit 2 and 6)
Reported as:
Geometric mean · Nanogram x hour/milliliter (ng*h/mL)
Derived Plasma GSK1278863 Pharmacokinetic Parameter -Area Under the Curve (AUC [0-t])
Nanogram x hour/milliliter (ng*h/mL)GSK1278863 300 mgGSK1278863 15 mg
Derived Plasma GSK1278863 Pharmacokinetic Parameter -Area Under the Curve (AUC [0-t])13059.70 ± 72.4383.81 ± 112.2
SecondaryDerived Plasma GSK1278863 Pharmacokinetic Parameter - Time to Maximum Plasma Concentration (T-max) and Last Time Point Where the Concentration is Above the Limit of Quantification (T-last)

Blood samples for pharmacokinetic analysis of GSK1278863 and selected metabolites were collected at the following time points: Visit 2-Baseline acute: pre-dose, 1 hour, 2 hours and 3.5 hours post-dose, Visit 3-post acute, Visit 4-rescreen, Visit 5-Baseline chronic and end of treatment or early termination. The actual date and time of each blood sample collection was recorded.

Time frame:
Visit 2 (Day 1): pre-dose, 1 hour, 2 hours and 3.5 hours post-dose, Visit 3 (Day 2)-post acute, Visit 4 (Day 16)-rescreen, Visit 5 (Day 23)-Baseline chronic and end of treatment (14 days after Visit 5) or early termination (between Visit 2 and 6)
Reported as:
Median · Hour
Derived Plasma GSK1278863 Pharmacokinetic Parameter - Time to Maximum Plasma Concentration (T-max) and Last Time Point Where the Concentration is Above the Limit of Quantification (T-last)
HourGSK1278863 300 mgGSK1278863 15 mg
Tmax1.016 (0.850 to 3.667)1.000 (0.833 to 3.583)
Tlast22.417 (3.42 to 24.47)3.500 (3.37 to 23.08)
SecondaryRelationship of Pharmacokinetic Parameters to the Pharmacodynamic Assessments Performed in This Study

A formal pharmacokinetic /pharmacodynamic analysis and pharmacokinetic /pharmacodynamic modelling for exposure relationships to endpoints was planned. The data for this outcome was not collected.

Time frame:
Visit 2 (Day 1): pre-dose, 1 hour, 2 hours and 3.5 hours post-dose, Visit 3 (Day 2)-post acute, Visit 4 (Day 16)-rescreen, Visit 5 (Day 23)-Baseline chronic and end of treatment (14 days after Visit 5) or early termination (between Visit 2 and 6)

No measurements were reported for this outcome.

Adverse events

Collected over Up to 67 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GSK1278863 300 mg0/26 (0%)2/26 (7.7%)10/26 (38.5%)
Placebo Matched With GSK1278863 300 mg0/20 (0%)0/20 (0%)6/20 (30%)
GSK1278863 15 mg0/23 (0%)0/23 (0%)3/23 (13%)
Placebo Matched With GSK1278863 15 mg0/19 (0%)1/19 (5.3%)3/19 (15.8%)
Most frequent serious events
Most frequent serious events
EventGSK1278863 300 mgPlacebo Matched With GSK1278863 300 mgGSK1278863 15 mgPlacebo Matched With GSK1278863 15 mg
Peripheral arterial occlusive diseaseVascular disorders0/260/200/231/19
Atrial fibrillationCardiac disorders1/260/200/230/19
Cardiac failure congestiveCardiac disorders1/260/200/230/19
HyponatraemiaMetabolism and nutrition disorders1/260/200/230/19
Lip and/or oral cavity cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/260/200/230/19
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders1/260/200/230/19
Most frequent other events
Showing 10 of 17
Most frequent other events
EventGSK1278863 300 mgPlacebo Matched With GSK1278863 300 mgGSK1278863 15 mgPlacebo Matched With GSK1278863 15 mg
DiarrhoeaGastrointestinal disorders3/260/200/230/19
Pain in extremityMusculoskeletal and connective tissue disorders3/260/202/230/19
DyspepsiaGastrointestinal disorders2/260/200/230/19
Upper respiratory tract infectionInfections and infestations2/260/200/230/19
FatigueGeneral disorders2/260/200/230/19
Back painMusculoskeletal and connective tissue disorders0/260/200/231/19
Oedema peripheralGeneral disorders0/260/200/231/19
HyperaesthesiaNervous system disorders0/260/200/231/19
Peripheral arterial occlusive diseaseVascular disorders0/260/200/231/19
FlatulenceGastrointestinal disorders0/261/200/230/19

Baseline characteristics

Age, Continuous
Age, Continuous(Years)GSK1278863PlaceboTotal
Mean68.4 ± 9.5069.4 ± 7.6568.8 ± 8.66
Sex: Female, Male
Sex: Female, Male(Participants)GSK1278863PlaceboTotal
Female7613
Male191433
Race (NIH/OMB)
Race (NIH/OMB)(Participants)GSK1278863PlaceboTotal
American Indian or Alaska Native000
Asian011
Native Hawaiian or Other Pacific Islander000
Black or African American7512
White191433
More than one race000
Unknown or Not Reported000
08

Study locations

12 sites
  • GSK Investigational Site
    Palo Alto, California 94304, United States
  • GSK Investigational Site
    Vista, California 92083, United States
  • GSK Investigational Site
    Clearwater, Florida 33761, United States
  • GSK Investigational Site
    Sarasota, Florida 34239, United States
  • GSK Investigational Site
    Chicago, Illinois 60612, United States
  • GSK Investigational Site
    Indianapolis, Indiana 46290, United States
  • GSK Investigational Site
    Boone, North Carolina 28607, United States
  • GSK Investigational Site
    Durham, North Carolina 27705, United States
  • GSK Investigational Site
    Toledo, Ohio 43606, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19104, United States
  • GSK Investigational Site
    San Antonio, Texas 78229, United States
  • GSK Investigational Site
    Norfolk, Virginia 23502, United States
09

References and documents

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2010 to primary completion in Nov 2011, 12 months.

Results were first posted in Oct 2017, 5 years 11 months after primary completion. A results delay was requested in May 2014.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2012
First posted
May 12, 2014
StartActual
Oct 15, 2010
Primary completionActual
Nov 1, 2011
CompletionActual
Nov 1, 2011
Results delay requested
May 29, 2014
Results first posted
Oct 20, 2017
Last update
Oct 20, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 20, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02135848
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
May 12, 2014
Start date
Oct 15, 2010
Primary completion
Nov 1, 2011
Completion
Nov 1, 2011
Results posted
Oct 20, 2017
Last update
Oct 20, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GSK1278863

Start the discussion